AZN.UK

12,500

+0.19%↑

GSK

1,600.5

-3.41%↓

HLN.UK

328.6

-0.67%↓

STJ

1,295

+1.45%↑

HIK

1,832

+1.05%↑

AZN.UK

12,500

+0.19%↑

GSK

1,600.5

-3.41%↓

HLN.UK

328.6

-0.67%↓

STJ

1,295

+1.45%↑

HIK

1,832

+1.05%↑

AZN.UK

12,500

+0.19%↑

GSK

1,600.5

-3.41%↓

HLN.UK

328.6

-0.67%↓

STJ

1,295

+1.45%↑

HIK

1,832

+1.05%↑

AZN.UK

12,500

+0.19%↑

GSK

1,600.5

-3.41%↓

HLN.UK

328.6

-0.67%↓

STJ

1,295

+1.45%↑

HIK

1,832

+1.05%↑

AZN.UK

12,500

+0.19%↑

GSK

1,600.5

-3.41%↓

HLN.UK

328.6

-0.67%↓

STJ

1,295

+1.45%↑

HIK

1,832

+1.05%↑

Kodu・Aktsiate loetelu・Oxford Biomedica PLC

O
Oxford Biomedica PLC

Avatud

610 2.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

571

Max

616

Põhinäitajad
By Trading Economics
Sissetulek	-11M
Müük	78M
Aktsiakasum	-0.11
Kasumimarginaal	-13.726
Töötajad	900
EBITDA	5M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+4.59% upside

Turustatistika
By TradingEconomics
Turukapital	671M
Eelmine avamishind	607.31
Eelmine sulgemishind	610

Oxford Biomedica PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. okt 2025, 23:30 UTC

Kuumad aktsiad

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. okt 2025, 21:21 UTC

Tulu

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. okt 2025, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. okt 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. okt 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. okt 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Scales's JV Buyout Lauded by Bull -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Forex and Fixed Income Roundup: Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. okt 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. okt 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

2. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. okt 2025, 20:49 UTC

Omandamised, ülevõtmised, äriostud

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. okt 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. okt 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. okt 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. okt 2025, 18:43 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Võrdlus sarnastega

Hinnamuutus

Oxford Biomedica PLC Prognoos

Hinnasiht

By TipRanks

4.59% tõus

12 kuu keskmine prognoos

Keskmine 617.053 GBX 4.59%

Kõrge 930 GBX

Madal 400 GBX

Põhineb 4 Wall Streeti analüütiku instrumendi Oxford Biomedica PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Oxford Biomedica PLC aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.